Macarulla Teresa, Adeva Jorge, Cano Osuna Maria Teresa, Ruiz Casado Ana, Jiménez Gordo Ana María, Lamarca Angela, López Muñoz Ana María, Pazo Cid Roberto Antonio, Saurí Tamara, Gallego Plazas Javier
Medical Oncology Department, Hospital Universitario Vall D'Hebron, Barcelona, Spain.
Medical Oncology Department, Hospital Universitario, 12 de Octubre, Madrid, Spain.
Clin Transl Oncol. 2025 May 30. doi: 10.1007/s12094-025-03916-y.
Biliary tract cancers (BTC) are aggressive and fatal. Early recognition of symptoms and proper diagnostic work up allow for precise histopathological and molecular classification as well as accurate evaluation of the extent of disease. Surgery is the only potentially curative therapy in localized stages; however, disease recurrence is common and adjuvant chemotherapy appears to improve survival. Upfront systemic chemotherapy with immunotherapy is the treatment of choice in unresectable locally-advanced and metastatic disease. Inroads made in understanding its molecular biology has enabled new therapeutic targets to be identified with current indications and encouraging results that could further improve BTC patients' survival and quality of life.
胆道癌(BTC)具有侵袭性且致命。早期识别症状并进行恰当的诊断检查,有助于进行精确的组织病理学和分子分类,以及准确评估疾病范围。手术是局限性阶段唯一可能治愈的疗法;然而,疾病复发很常见,辅助化疗似乎能提高生存率。对于不可切除的局部晚期和转移性疾病,一线采用免疫疗法的全身化疗是首选治疗方法。在理解其分子生物学方面取得的进展,使得能够确定新的治疗靶点,目前已有相关适应证且结果令人鼓舞,有望进一步提高BTC患者的生存率和生活质量。